FDA approves semaglutide for specific MASH patient groups

The U.S. Food and Drug Administration (FDA) has granted approval for semaglutide to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) characterized by moderate to advanced fibrosis without cirrhosis. This approval is specific to certain stages of the disease and does not constitute a general clearance for all forms of fatty liver disease.

The decision comes amid high global demand, with reports indicating that the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is approximately 38 percent, affecting roughly one in four adults worldwide.

While semaglutide gains traction, medical experts emphasize the importance of precise risk stratification and early intervention. Other regulatory developments include preliminary approval for Wegovy in Australia for non-cirrhotic MASH and approvals for related obesity medications in India and China. Potential side effects of semaglutide include gastrointestinal issues such as nausea and diarrhea, potential psychological impacts, and weight regain following discontinuation of the medication.